TENX Stock Forecast: Tenax Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Tenax Therapeutics, Inc. is $5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 24 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Tenax Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (63): Analysts have, on balance, been raising their forecasts.
Momentum (15): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
TENX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TENX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Aug 2026 | Guggenheim | Downgrade | Neutral | — |
| 11 Aug 2026 | Canaccord Genuity | Maintains | Buy | $35 → $4.00 |
| 11 Aug 2026 | Chardan Capital | Downgrade | Neutral | $27 → $5.00 |
| 11 Aug 2026 | Evercore ISI Group | Downgrade | In-Line | $39 → $5.00 |
| 11 Aug 2026 | Guggenheim | Maintains | Buy | $40 → $4.00 |
| 10 Aug 2026 | William Blair | Downgrade | Market Perform | — |
| 31 July 2026 | Chardan Capital | Maintains | Buy | $27 |
| 29 July 2026 | Cantor Fitzgerald | Reiterates | Overweight | $35 |
| 28 July 2026 | Canaccord Genuity | Initiates | Buy | $35 |
| 22 July 2026 | Evercore ISI Group | Initiates | Outperform | $39 |
| 2 July 2026 | Chardan Capital | Maintains | Buy | $27 |
| 24 June 2026 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 22 June 2026 | Chardan Capital | Initiates | Buy | — |
| 22 June 2026 | Guggenheim | Maintains | Buy | — |
| 12 June 2026 | Piper Sandler | Maintains | Overweight | — |
| 17 Mar 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 16 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 17 Dec 2025 | Guggenheim | Maintains | Buy | — |
| 8 Sept 2025 | Piper Sandler | Initiates | Overweight | — |
| 14 Aug 2025 | Guggenheim | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TENX.
This page is one stock. Monday covers all of them.
TENX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
TENX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Tenax Therapeutics, Inc. returned −83.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
TENX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.6×
- EV / EBITDA
- —
Cheaper than 83% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −64.2%
- Return on assets
- −39.5%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Tenax Therapeutics, Inc. has a market value of $63.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$64.9M.
Free cash flow in the twelve months to 30 June 2026: −$46.0M.
Tenax Therapeutics, Inc. employs 14 people.
Data provided by Twelve Data
TENX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at TENX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Tenax Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about TENX
What is the TENX stock price forecast for 2026-2027?
The median 12-month analyst price target for Tenax Therapeutics, Inc. is $5, with estimates ranging from $4 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is TENX stock a buy right now?
Of the 10 analysts covering Tenax Therapeutics, Inc., 6 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tenax Therapeutics, Inc. 24 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TENX?
As at 21 Nov 2026, Tenax Therapeutics, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (63 of 100).
Will TENX stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts is $5, and Ticker Nerd's factor model ranks Tenax Therapeutics, Inc. 24 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the TENX stock forecast for 2030?
No analyst covering Tenax Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TENX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $35 over the next 12 months.
How has TENX stock performed over the past year?
Tenax Therapeutics, Inc. returned -83.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Tenax Therapeutics, Inc. do?
Tenax Therapeutics, Inc. is a development-stage pharmaceutical company focused on cardiopulmonary therapies. The company develops treatments for serious cardiovascular and pulmonary conditions, with a primary emphasis on pulmonary hypertension associated with heart failure with preserved ejection fraction.
About Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a development-stage pharmaceutical company focused on cardiopulmonary therapies. The company develops treatments for serious cardiovascular and pulmonary conditions, with a primary emphasis on pulmonary hypertension associated with heart failure with preserved ejection fraction. Its pipeline includes levosimendan-based programs, as well as other drug candidates aimed at improving outcomes in heart and lung disease. Tenax Therapeutics concentrates on advancing clinical-stage therapies for patients with high unmet medical needs, making it a specialized player in the pharmaceutical market. Headquartered in Chapel Hill, North Carolina, Tenax Therapeutics operates as a research-driven company centered on novel treatments for complex cardiopulmonary disorders.
CEO Mr. Christopher T. Giordano · 14 employees · United States · https://www.tenaxthera.com